COWART Marlon D.;GFESSER Gregory A.;GALAPAGOS NV;BOGDAN Andrew;AbbVie S.A.R.L.;MALAGU Karine Fabienne;ESMIEU William Ramesh;LIU Bo;KYM Philip R.;KOENIG John R.;GRESZLER Stephen N.;ALTENBACH Robert J.
发明人:
ALTENBACH Robert J.,BOGDAN Andrew,COWART Marlon D.,ESMIEU William Ramesh,GFESSER Gregory A.,GRESZLER Stephen N.,KOENIG John R.,KYM Philip R.,LIU Bo,MALAGU Karine Fabienne,PATEL Sachin V.,SCANIO Marc J
申请号：
IL25685118
公开号：
IL256851A
申请日:
2018.01.11
申请国别(地区):
IL
年份:
2020
代理人:
摘要：
wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
